Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc

RefinitivLess than 1 min read

Zai Lab Ltd 9688:

ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATING ROBUST ANTI-TUMOR ACTIVITY AND SAFETY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER AT 2025 ASCO ANNUAL MEETING

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Login or create a forever free account to read this news